MedTrace Logo

Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19

NCT04499313 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-08-18

No results posted yet for this study

Summary

A randomized clinical trial designed and intended to evaluate the efficacy of Dexamethasone and Methylprednisolone as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by coronavirus disease 19 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.

Conditions

  • Covid19
  • ARDS

Interventions

DRUG

Dexamethasone

Injectable solution

DRUG

Methylprednisolone

Injectable solution

Sponsors & Collaborators

  • Xi'an Jiaotong University

    collaborator OTHER

  • Chattogram General Hospital

    lead OTHER_GOV

Principal Investigators

  • Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD · First Affiliated Hospital Xi'an Jiaotong University

  • Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD · First Affiliated Hospital Xi'an Jiaotong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-02
Primary Completion
2020-11-15
Completion
2020-11-30

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04499313 on ClinicalTrials.gov